| Literature DB >> 28137312 |
Ling Zhang1,2, Yunhao Liu3, Wei Li4, Qiaoling Zhang5, Yanwei Li4,6, Junpin Liu4,7, Jie Min3, Chaofan Shuang3, Shizheng Song3, Zhibing Zhang8.
Abstract
BACKGROUND: The mammalian sperm-associated antigen 16 gene (Spag16) uses alternative promoters to produce two major transcript isoforms (Spag16L and Spag16S) and encode proteins that are involved in the cilia/flagella formation and motility. In silico analysis of both mouse and human SPAG16L promoters reveals the existence of multiple putative SOX5 binding sites. Given that the SOX5 gene encodes a 48-kDa transcription factor (S-SOX5) and the presence of putative SOX5 binding sites at the SPAG16L promoter, regulation of SPAG16L expression by S-SOX5 was studied in the present work.Entities:
Keywords: Central apparatus; Cilia; S-SOX5; SPAG16L; Transcriptional regulation
Mesh:
Substances:
Year: 2017 PMID: 28137312 PMCID: PMC5282894 DOI: 10.1186/s12867-017-0082-3
Source DB: PubMed Journal: BMC Mol Biol ISSN: 1471-2199 Impact factor: 2.946
Fig. 1Effect of S-SOX5 on the human SPAG16L promoter activity. 2-kb human SPAG16L promoter construct was transfected to BEAS-2B cells. The cells were also co-transfected with S-SOX5/pcDNA3 or empty pcDNA3 plasmid. The promoter activity was measured by dual luciferase assays after 48 h transfection. Values indicate mean ± S.E. (error bars) of the relative luciferase activity (n = 3). *p < 0.05 (Student’s t test) compared to the control
Fig. 2Exogenous S-SOX5 up-regulates SPAG16L mRNA expression in BEAS-2B cells. a Western blot analysis of S-SOX5 protein levels in BESA-2B cells stably expressing S-SOX5 (left) or infected with AdS-SOX5 (right) detected with the Pico system. b Analysis of SPAG16L mRNA expression by real-time PCR. GAPDH was also amplified simultaneously to normalize the results. Values indicate mean ± S.E. (error bars) of the relative mRNA level (n = 3). *p < 0.05 (Student’s t test) compared to the controls
Fig. 3Knockdown of S-SOX5 in BEAS-2B cells by RNAi results in decrease of SPAG16L mRNA. a Western blot analysis of S-SOX5 proteins in BEAS-2B cells stably expressing two RNAi constructs. b After RNAi treatment, the levels of S-SOX5 in BEAS-2B cells were estimated by analysing intensity of protein bands using ImageJ software. c Analysis of SPAG16L mRNA expression by real-time PCR in BEAS-2B cells transfected with two SOX5 RNAi constructs. Silencing of S-SOX5 by RNAi reduced expression of SPAG16L. Values indicate mean ± S.E. (error bars) of the relative mRNA level (n = 3). *p < 0.05 (Student’s t test) compared to the control
Fig. 4S-SOX5 associates with the human SPAG16L promoter as revealed by ChIP assay. A Schematic representation of the human SPAG16L proximal promoter and the regions (a–c) amplified by ChIP primers used in this study. Arrows show the location of the primers. B Representative ChIP assay results with BEAS-2B cells infected by AdS-SOX5 using a control rabbit IgG or an antibody specifically against SOX5. a with a primer set not flanking any potential SOX5 binding sites; b and c, with primer sets flanking potential SOX5 binding sites. C qPCR quantification of ChIP products. DNA recovered from ChIP was used as a template for real-time PCR analysis. Data shown are mean ± S.E. (error bars) of three independent replicates. *p < 0.05 (Student’s t test) compared to the normal rabbit IgG pulldown group
Fig. 5Functional analyses of S-SOX5 binding sites in the human SPAG16L promoter. Left maps of the wild-type human SPAG16L promoter construct containing two putative SOX5 binding sites (P-I & P-II) and the constructs with mutations of the potential SOX5 binding sites. Right, effect of S-SOX5 on the function of the wild-type and mutated SPAG16L promoter. BEAS-2B cells were co-transfected with SPAG16L promoter constructs and either pcDNA3 control or S-SOX5/pcDNA3. Relative luciferase activity, normalized to pGL3 control plasmids co-transfected with pcDNA3 vectors. Values are mean ± S.E. (error bars) of the relative luciferase activity (n = 3). Bars labeled with different letters are significantly different (p < 0.05; two-way ANOVA with Tukey’s HSD test)
Oligonucleotides used in this study
| Primer name | Sequence (5′–3′) | Application |
|---|---|---|
| SPAG16L-promoterF1 | GGTACCGGTCAAAGCGAAAGAAAACC | Forward primer for transcription fusion to |
| SPAG16L-promoterR2 | CTCGAGGAACAGCGAAGACGCTACCC | Reverse primer for transcription fusion to |
| Human S-SOX5 forward | GTGCCATAGGAGCTGTGCATG | S-SOX5 expression |
| Human S-SOX5 reverse | GTTGGTCCTTCATTTGCCGAGC | |
| SOX5 RNAi (225) sense | AAAAATGATGCTGTCACCAAGGCAA | SOX5 RNAi construction |
| SOX5 RNAi (225) anti-sense | AAAGTTGCCTTGGTGACAGCATCAT | |
| SOX5 RNAi (1109) sense | AAAAGATTATGGGAGTGACAGTGAA | SOX5 RNAi construction |
| SOX5 RNAi (1109) anti-sense | AAAGTTCACTGTCACTCCCATAATC | |
| SPAG16L RT-PCRF | TTCAGACTGCTGCTTCCATC | Real-time PCR analysis of SPAG16L |
| SPAG16L RT-PCRR | TCGCCTGTACATAGATCCCA | |
| GAPDH RT-PCRF | GGAGGTGAAGGTCGGAGTC | Real-time PCR analysis of GAPDH |
| GAPDH RT-PCRR | GAAGATG GTGATGGGATTTC | |
| SPAG16L mutation 1F | TGCAATGCAAGCCAACCACCTACTGTATCTTGTCC | Mutation of SOX5 binding site (P-I site) at SPAG16L promoter |
| SPAG16L mutation 1R | GGACAAGATACAGTAGGTGGTTGGCTTGCATTGCA | |
| SPAG16L mutation 2F | GTTAACTAGGCAACACTACCGCCACGGTAACTGGG | Mutation of SOX5 binding site (P-II site) at SPAG16L promoter |
| SPAG16L mutation 2R | CCCAGTTACCGTGGCGGTAGTGTTGCCTAGTTAAC | |
| SPAG16L ChIP-aF | CTTGGGTGACTTCCAATTTTG | ChIP assays for SPAG16L site a |
| SPAG16L ChIP-aR | GTATCATTAACTACACTCCTC | |
| SPAG16L ChIP-bF | CCTACTTGAGGAGGAGAGTGGGA | ChIP assays for SPAG16L site b |
| SPAG16L ChIP-bR | TATCGCGTATGTATCAGAAGC | |
| SPAG16L ChIP-cF | GGAAGATCCTCTCAGCAATAAGAC | ChIP assays for SPAG16L site c |
| SPAG16L ChIP-cR | GAAGAACTATGGTGTTCAGC |